Neu H C, Fu K P
Antimicrob Agents Chemother. 1979 Feb;15(2):209-12. doi: 10.1128/AAC.15.2.209.
Cefatrizine, a new orally administered cephalosporin, was tested against 400 clinical isolates. Cefatrizine had excellent activity against gram-positive cocci, inhibiting all except enterococci at minimal inhibitory concentrations below 1 mug/ml. Cefatrizine inhibited the majority of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella at concentrations below 12.5 mug/ml. Although cefatrizine was not hydrolyzed by many beta-lactamases, it did not inhibit a number of strains of Enterobacter, Serratia, or indole-positive Proteus. Cefatrizine was more active than cephalothin or cephalexin against E. coli, Klebsiella, Enterobacter, Citrobacter, Salmonella, and Shigella. Its overall activity was less than that of cefoxitin against strains resistant to cephalothin, but its activity against cephalothin-susceptible strains was equivalent to that of cefamandole.
头孢曲嗪是一种新的口服头孢菌素,对400株临床分离菌进行了测试。头孢曲嗪对革兰氏阳性球菌具有优异的活性,在最低抑菌浓度低于1微克/毫升时,除肠球菌外,对所有菌株均有抑制作用。头孢曲嗪在浓度低于12.5微克/毫升时,可抑制大多数大肠杆菌、肺炎克雷伯菌、奇异变形杆菌和沙门氏菌。虽然头孢曲嗪不被许多β-内酰胺酶水解,但它不能抑制一些阴沟肠杆菌、沙雷氏菌或吲哚阳性变形杆菌菌株。头孢曲嗪对大肠杆菌、克雷伯菌、阴沟肠杆菌、柠檬酸杆菌、沙门氏菌和志贺氏菌的活性比头孢噻吩或头孢氨苄更强。它对耐头孢噻吩菌株的总体活性低于头孢西丁,但对头孢噻吩敏感菌株的活性与头孢孟多相当。